Drug Profile
Research programme: microencapsulated oral insulin - Response Scientific
Alternative Names: RSM 063Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Response Scientific
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for research development in Diabetes-mellitus in USA (PO)
- 27 Feb 2014 Early research in Diabetes mellitus in USA (PO)